Issue Date: September 5, 2011
Biogen, Novo Tap Adimab Technology
Adimab has added partners looking to exploit its yeast-based antibody discovery technology. In separate deals, Biogen Idec and Novo Nordisk will each provide two drug targets against which Adimab will identify fully human antibodies. Adimab stands to gain up-front payments and milestones if any products move into the clinic. The Lebanon, N.H.-based firm also says it has achieved technical milestones in its collaborations with Merck & Co., Novartis, Pfizer, and Human Genome . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society